Clinical Trial Update: Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 study comparing BCD-217 followed by BCD-100 versus BCD-100 monotherapy as first-line treatment in unresectable or metastatic melanoma; status is unknown…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• BCD-100 (unclear)
• BCD-217 (Nurulimab + Proglolimab)

Snippet

Sponsor: Biocad | Conditions: Melanoma, Melanoma Metastatic | Phase 2 | Status: UNKNOWN